PMV Pharmaceuticals (PMVP) Cash & Equivalents (2019 - 2026)

PMV Pharmaceuticals (PMVP) has 8 years of Cash & Equivalents data on file, last reported at $39.0 million in Q1 2026.

• Quarterly Cash & Equivalents fell 23.96% year-over-year to $39.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.0 million (down 23.96% YoY) and the FY2025 annual result came in at $37.9 million, down 7.31% from the prior year.
• Cash & Equivalents grew to $39.0 million in Q1 2026, from $37.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $142.9 million in Q1 2023 to a low of $36.3 million in Q3 2025.
• A 5-year average of $64.9 million and a median of $48.8 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents climbed 25.09% — and 2024, when it plunged 66.66%.
• Tracing PMVP's Cash & Equivalents over 5 years: stood at $108.3 million in 2022, then plunged by 65.18% to $37.7 million in 2023, then rose by 8.41% to $40.9 million in 2024, then declined by 7.31% to $37.9 million in 2025, then gained by 3.03% to $39.0 million in 2026.
• The last three Cash & Equivalents figures came in at $39.0 million (Q1 2026), $37.9 million (Q4 2025), and $36.3 million (Q3 2025), per Business Quant data.